TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT)
Brief Summary: The purpose of the study is to understand whether the drug praziquantel (PZQ) is safe for the mother and developing baby when the mother has schistosomiasis (a type of worm) infection, and whether the drug may improve the mother's and baby's health. The usual practice is to wait until after a mother has finished breast feeding before giving the medicine. Approximately 375 infected pregnant women, ages 18 and over, in endemic villages in Leyte, The Philippines will participate. Study volunteers 12-16 weeks pregnant will be given PZQ or an inactive pill (placebo) and stay in the hospital overnight. Small blood samples will be collected before and after the medication is taken. Three stool and urine samples will be taken during a total of 7 study visits. An ultrasound image (picture or outline of the unborn baby) will be performed. When the baby is born, a small blood sample will be taken. Mother and baby will be followed for up to 8 months before the baby is born and 1 month after.


Options:
A: Arm Label: Community-wide deworming; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: Targeted deworming; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albendazole | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Community-wide deworming, Targeted deworming
B: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Praziquantel; Type: EXPERIMENTAL; Interventions: Drug: Praziquantel | Intervention Type: DRUG; Name: Praziquantel; Assigned to Arm(s): Praziquantel | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control
C: Arm Label: Mefloquine; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine | Arm Label: S/P; Type: PLACEBO_COMPARATOR; Interventions: Drug: S/P | Intervention Type: DRUG; Name: Mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: S/P; Assigned to Arm(s): S/P
D: Arm Label: Albendazole; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Lifestyle Intervention in Primary Health Care for the Modification of Cardiovascular Risk Factors - the Björknäs Study
Brief Summary: The purpose of this study is to determine whether a short group intervention programe aiming at lifestyle changes at a local health centre can improve risk factors for cardiovascular disease


Options:
A: Arm Label: Conventional Health Promotion Education (CHPE).; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CHPE | Arm Label: PRECEDE HPE model; Type: EXPERIMENTAL; Interventions: Behavioral: PRECEDE HPE model | Intervention Type: BEHAVIORAL; Name: PRECEDE HPE model; Assigned to Arm(s): PRECEDE HPE model | Intervention Type: BEHAVIORAL; Name: CHPE; Assigned to Arm(s): Conventional Health Promotion Education (CHPE).
B: Arm Label: Control-group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control-group | Arm Label: Intervention-group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention-group | Intervention Type: BEHAVIORAL; Name: Intervention-group; Assigned to Arm(s): Intervention-group | Intervention Type: BEHAVIORAL; Name: Control-group; Assigned to Arm(s): Control-group
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Virtual Coach software | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Activity monitor and website | Intervention Type: OTHER; Name: Virtual Coach software; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Activity monitor and website; Assigned to Arm(s): Control
D: Intervention Type: BEHAVIORAL; Name: Exercise and diet - based on DPS and DPP; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Lifestyle Intervention in Primary Health Care for the Modification of Cardiovascular Risk Factors - the Björknäs Study
Brief Summary: The purpose of this study is to determine whether a short group intervention programe aiming at lifestyle changes at a local health centre can improve risk factors for cardiovascular disease


Options:
A: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
B: Arm Label: lifestyle intervention; Type: EXPERIMENTAL; Interventions: Other: lifestyle intervention | Intervention Type: OTHER; Name: lifestyle intervention; Assigned to Arm(s): lifestyle intervention
C: Intervention Type: BEHAVIORAL; Name: Exercise and diet - based on DPS and DPP; Assigned to Arm(s): N/A
D: Arm Label: Standard Behavioral Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Treatment | Arm Label: SBT+LOV Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Treatment, Behavioral: SBT+LOV | Intervention Type: BEHAVIORAL; Name: Standard Behavioral Treatment; Assigned to Arm(s): SBT+LOV Group, Standard Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: SBT+LOV; Assigned to Arm(s): SBT+LOV Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Respiratory muscle strength is used as an outcome measure in intervention studies. There are reference values for respiratory muscle strength in 'healthy' people but not in those with bronchiectasis disease. The aim of this study is to investigate the reliability of respiratory muscle strength measurements and identify reference values for those with stable moderate to severe bronchiectasis disease.


Options:
A: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
B: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia
Brief Summary: The purpose of this randomized, open label clinical trial is to determine if oral miltefosine is a safe and effective alternative, compared with parenteral meglumine antimoniate for the treatment of pediatric Cutaneous caused by L. Viannia species in Colombia.


Options:
A: Arm Label: Paromomycin Alone Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paromomycin Alone Cream (15% paromomycin topical cream) | Arm Label: WR 279,396; Type: ACTIVE_COMPARATOR; Interventions: Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) | Intervention Type: DRUG; Name: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Paromomycin Alone Cream (15% paromomycin topical cream); Assigned to Arm(s): Paromomycin Alone Treatment
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Miltefosine | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine antimoniate | Intervention Type: DRUG; Name: Miltefosine; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Meglumine antimoniate; Assigned to Arm(s): Group 2
C: Arm Label: Topical Amphotericin B three times per day; Type: EXPERIMENTAL; Interventions: Drug: Topical Amphotericin B at 3% | Arm Label: Topical Amphotericin B two times per day; Type: EXPERIMENTAL; Interventions: Drug: Topical Amphotericin B at 3% | Intervention Type: DRUG; Name: Topical Amphotericin B at 3%; Assigned to Arm(s): Topical Amphotericin B three times per day, Topical Amphotericin B two times per day
D: Intervention Type: BIOLOGICAL; Name: Leish-111f + MPL-SE vaccine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Golimumab 100 mg -> 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 50 mg | Arm Label: Golimumab 200 mg -> 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Golimumab 400 mg -> 200 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 200 mg, Biological: Golimumab 400 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg, Golimumab 200 mg -> 100 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): Golimumab 200 mg -> 100 mg, Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 400 mg; Assigned to Arm(s): Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: methotrexate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 9 mg | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Arm Label: 4: Asacol® 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Asacol® 400 mg | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Placebo, 4: Asacol® 400 mg | Intervention Type: DRUG; Name: budesonide-MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: budesonide-MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3: Placebo | Intervention Type: DRUG; Name: Asacol® 400 mg; Assigned to Arm(s): 4: Asacol® 400 mg
D: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).


Options:
A: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: rhuMAb Beta7; Type: EXPERIMENTAL; Interventions: Drug: rhuMAb Beta7 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: rhuMAb Beta7; Assigned to Arm(s): rhuMAb Beta7
C: Arm Label: Adalimumab 80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 160/80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80/40 | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160/80/40 | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Golimumab 100 mg -> 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 50 mg | Arm Label: Golimumab 200 mg -> 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Golimumab 400 mg -> 200 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 200 mg, Biological: Golimumab 400 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg, Golimumab 200 mg -> 100 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): Golimumab 200 mg -> 100 mg, Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 400 mg; Assigned to Arm(s): Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).


Options:
A: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Golimumab 100 mg -> 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 50 mg | Arm Label: Golimumab 200 mg -> 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Golimumab 400 mg -> 200 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 200 mg, Biological: Golimumab 400 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg, Golimumab 200 mg -> 100 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): Golimumab 200 mg -> 100 mg, Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 400 mg; Assigned to Arm(s): Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg
C: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1 (i); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2 (ii); Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 (i), 2 (ii)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia
Brief Summary: The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil (Nuvigil) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil (Nuvigil); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: modafinil; Type: EXPERIMENTAL; Interventions: Drug: modafinil | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: modafinil; Assigned to Arm(s): modafinil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: 150 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 200 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 250 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 150 mg/day armodafinil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Matching Placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 200 mg/day armodafinil | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 250 mg/day armodafinil
D: Arm Label: 50 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 100 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 200 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 50 mg/day armodafinil | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 100 mg/day armodafinil | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 200 mg/day armodafinil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Teledermatology on Health Services Outcomes in the VA
Brief Summary: This study compares store and forward teledermatology with the conventional clinic-based consult process. Our primary objective is to determine whether the mean change in quality of life, as rated by the subscale scores and composite score on the Skindex-16 differs between the store and forward and conventional care modalities.


Options:
A: Arm Label: Standard consultation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care in orthopaedic outpatient clinic | Arm Label: Telemedicine consultation; Type: EXPERIMENTAL; Interventions: Other: Telemedicine consultation | Intervention Type: OTHER; Name: Telemedicine consultation; Assigned to Arm(s): Telemedicine consultation | Intervention Type: OTHER; Name: Standard care in orthopaedic outpatient clinic; Assigned to Arm(s): Standard consultation
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Procedure: Store and forward teledermatology | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Store and forward teledermatology; Assigned to Arm(s): Arm 1
C: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
D: Arm Label: Technology supported supervision; Type: EXPERIMENTAL; Interventions: Other: Technology supported supervision, Other: Integrated community case management | Arm Label: Community supported supervision; Type: EXPERIMENTAL; Interventions: Behavioral: Community supported supervision, Other: Integrated community case management | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated community case management | Intervention Type: OTHER; Name: Technology supported supervision; Assigned to Arm(s): Technology supported supervision | Intervention Type: BEHAVIORAL; Name: Community supported supervision; Assigned to Arm(s): Community supported supervision | Intervention Type: OTHER; Name: Integrated community case management; Assigned to Arm(s): Community supported supervision, Control arm, Technology supported supervision

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-Pneumatic Anti-Shock Garment for Obstetrical Hemorrhage: Zambia and Zimbabwe
Brief Summary: This trial will address the question of whether early application of the Non-pneumatic Anti-Shock Garment (NASG) at the Satellite Health Facility (SHF) level before transport to a Referral Hospital (RH) will decrease maternal mortality and morbidity. The available evidence indicates that the NASG substantially decreases blood loss, but there is no evidence that its application will reduce extreme adverse outcomes. It is also not known if possible side effects associated with NASG use might outweigh potential benefits. This study would rigorously test the effectiveness of the NASG using an experimental design with adequate power to detect statistically significant decreases in morbidity and mortality.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Device: non-pneumatic anti-shock garment | Intervention Type: DEVICE; Name: non-pneumatic anti-shock garment; Assigned to Arm(s): Intervention
B: Arm Label: Room temperature arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Cold Bakri Balloon | Arm Label: Cold arm; Type: EXPERIMENTAL; Interventions: Device: Cold Bakri Balloon | Intervention Type: DEVICE; Name: Cold Bakri Balloon; Assigned to Arm(s): Cold arm, Room temperature arm
C: Arm Label: Celox group; Type: ACTIVE_COMPARATOR; Interventions: Device: Celox group | Arm Label: Bakri balloon group; Type: ACTIVE_COMPARATOR; Interventions: Device: Bakri Balloon | Intervention Type: DEVICE; Name: Celox group; Assigned to Arm(s): Celox group | Intervention Type: DEVICE; Name: Bakri Balloon; Assigned to Arm(s): Bakri balloon group
D: Arm Label: Baseline period; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Uterine balloon tamponade; Type: EXPERIMENTAL; Interventions: Other: Uterine balloon tamponade | Intervention Type: OTHER; Name: Uterine balloon tamponade; Assigned to Arm(s): Uterine balloon tamponade

Answer: A